Immune system boosters tested against Tough-to-Treat breast cancer
NCT ID NCT03789110
Summary
This study is testing whether a combination of two immunotherapy drugs, nivolumab and ipilimumab, can help control advanced breast cancer that has spread and has a high number of genetic mutations. The trial is enrolling 30 people with a specific type of breast cancer (HER2-negative) to see if the drug combination can shrink tumors. Researchers will also look for markers in the blood or tumor that might predict which patients benefit most.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.